Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.78 |
| ▸ | CES1 | P23141 | 1/20 | 0.78 |
| ▸ | DAO | P14920 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71972 | 0.81 | — | — | |
| SCHEMBL14854122 | 0.80 | CES2 (0.75) | CES2CES1DAOGSK3BKMT2A | |
| SCHEMBL14854150 | 0.80 | CES2 (0.75) | CES2CES1DAOGSK3BKMT2A | |
| SCHEMBL13437714 | 0.79 | CES2 (0.73) | CES2CES1DAOGSK3BKMT2A | |
| SCHEMBL28774604 | 0.78 | DAO (0.63) | CES2CES1DAOGSK3BKMT2A | |
| SCHEMBL1244072 | 0.78 | CES2 (0.73) | CES2CES1DAOGSK3BKMT2A | |
| SCHEMBL10915819 | 0.75 | DAO (0.59) | CES2CES1DAOGSK3BKMT2A | |
| SCHEMBL1455897 | 0.74 | — | — | |
| SCHEMBL345568 | 0.74 | — | — | |
| SCHEMBL1476181 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2764034-B1 | POLYMERS BASED ON BENZODIONES | CLAP CO LTD (KR) | 2023-08-30 | — | — | EP | disclosed |
| US-9240551-B2 | Polymers based on benzodiones | BASF SE (DE) | 2016-01-19 | — | — | US | disclosed |
| US-9240551-B2 | Polymers based on benzodiones | BASF SE (DE) | 2016-01-19 | — | — | US | disclosed |
| US-20140302637-A1 | POLYMERS BASED ON BENZODIONES | BASF SE (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140302637-A1 | POLYMERS BASED ON BENZODIONES | BASF SE (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2013050401-A2 | POLYMERS BASED ON BENZODIONES | BASF SE (DE) | 2013-04-11 | — | — | WO | disclosed |
| US-7846671-B2 | Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846671-B2 | Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846671-B2 | Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7718670-B2 | Quinuclidine amide derivatives | LABORATORIOS ALMIRALL S.A (ES) | 2010-05-18 | — | — | US | disclosed |
| EP-1499279-A2 | MOLECULES THAT MODULATE GaQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040014135-A1 | Molecules that modulate Galphaq avtivity and methods of treating urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-22 | — | — | US | disclosed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| US-6613786-B2 | Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| WO-2003063784-A2 | MOLECULES THAT MODULATE GαQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | HEWAWASAM PIYASENA (US) | 2003-07-31 | — | — | US | disclosed |
| EP-0861242-B1 | HETEROCYCLIC FUNGICIDES | AVENTIS CROPSCIENCE UK LTD (GB) | 2001-05-30 | — | — | EP | disclosed |
| US-6034121-A | AGRICULTURE | AGREVO UK LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| EP-0861242-A1 | HETEROCYCLIC FUNGICIDES | AgrEvo UK Limited (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997013762-A1 | HETEROCYCLIC FUNGICIDES | AGREVO UK LIMITED (GB) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | PDE3A, ADRB2, ADRB3 | CES2 2835/4885CES1 945/4885DAO 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.